Artelo Biosciences, Inc(NASDAQ:ARTL) 
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for ...
Website: https://artelobio.com/
Founded: 2011
CEO: Gregory Gorgas
Sector: Manufacturing
Industry: Tobacco Manufacturing
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 5.46
H 5.52
L 5.10
C 5.52
V 47,511
10EMA 5.52
20EMA 5.52
60EMA 5.52
120EMA 5.52
250EMA 5.52